- Home
- RMR vs PBYI Comparison
RMR vs PBYI Comparison
Compare RMR & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMR | PBYI |
|---|---|---|
| Founded | 1986 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.9M | 263.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RMR | PBYI |
|---|---|---|
| Price | $15.32 | $6.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $17.00 | $7.00 |
| AVG Volume (30 Days) | 174.4K | ★ 401.1K |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 11.89% | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | ★ 1.03 | 0.74 |
| Revenue | $196,824,000.00 | ★ $211,995,000.00 |
| Revenue This Year | $251.56 | N/A |
| Revenue Next Year | $3.20 | N/A |
| P/E Ratio | $14.70 | ★ $8.49 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.48 | $2.58 |
| 52 Week High | $19.24 | $7.21 |
Technical Indicators
Market Signals| Indicator | RMR | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 42.87 | 56.98 |
| Support Level | $15.08 | $6.26 |
| Resistance Level | $16.52 | $6.64 |
| Average True Range (ATR) | 0.34 | 0.29 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 16.70 | 36.77 |
Price Performance
Historical ComparisonAbout RMR The RMR Group Inc.
The RMR Group Inc is a holding company that conducts its business through its subsidiary, which is an alternative asset management company that invests in real estate and manages real estate-related businesses. Its business consists of providing management services to publicly owned real estate investment trusts, or REITs, and real estate-related operating companies. It also provides management services to real estate securities mutual funds and commercial real estate finance companies. The company's operating segment is RMR LLC and All Other Operations. The RMR Group derives its revenue from providing business and property management services as well as advisory and other services.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.